USA – SAN DIEGO, CA, Ambrx has announced the closing of an oversubscribed $200 million crossover financing round. Ambrx, a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code announced today the successful closing of an oversubscribed $200 million crossover financing round. New investors include Fidelity Management & Research Company LLC, […]
